Home
HomeSite Index Maps & Directions Contact Us
Find a Doctor
Consumer Health Information
About University Health Systems
Patient and Visitor Information
Jobs
Graduate Medical Education
Our Hospitals
Pitt County Memorial Hospital
Bertie Memorial Hospital
Chowan Hospital
Heritage Hospital
The Outer Banks Hospital
Roanoke-Chowan Hospital
Cardiovascular Center
Children's Hospital
Leo Jenkins Cancer Center
Regional Rehabilitation Center
Trauma and Critical Care
Women's Services
Surgical Services
Outpatient Services
ViQuest
All Services
Quick Links








Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Molecule Uses Cellular Recycling to Treat Kidney Cancer


Finding represents a major shift for targeted therapy, study says

MONDAY, July 7 (HealthDay News) -- A molecule that uses a cellular recycling process called autophagy to kill cancer cells has been identified by Stanford University researchers.

Autophagy is normally used by cells to conserve resources during times of stress.

"Increasing evidence implicates a role for autophagy in cancer, but it is not well understood how cellular and environmental cues drive authophagic cells down survival or death pathways," study senior author Dr. Amato J. Giaccia said in a prepared statement.

In this study, Giaccia and his colleagues focused on renal cell carcinoma (RCC), the most common form of kidney cancer. In most cases, RCC is caused by a mutation of the von Hippel-Lindau (VHL) tumor suppressor gene and often fails to respond to treatment.

"Since RCCs have a poor prognosis and are refractory to standard chemotherapy, there is a need to develop new therapies for kidney cancer," Giaccia said.

The researchers searched for molecules that could destroy VHL-deficient kidney cancer and identified a molecule called STF-62247, which enhanced autophagy in VHL-deficient cells. The molecule didn't affect cells with normal VHL.

"We have found a small molecule that selectively induces cell death in VHL-deficient cells, such as those that are found in kidney cancer. This represents a paradigm shift for targeted therapy," Giaccia said.

The study was to be published in the July 8 issue of the journal Cancer Cell.

More information

The American Cancer Society has more about kidney cancer.

SOURCE: Cell Press, news release, July 7, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision
Disclaimer Information Calendar of Events Privacy Practices Copyright 2005